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Abbreviations         I. 
 
VAA-I  Viscum album agglutinin-I 
LGL  Large granular lymphocytes 
PBMC  Peripheral mononuclear cells 
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NK cells Natural killer cells 
PMN  Polymorphonuclear leukocytes 
M  Macrophages 
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TAM  Tumor associated macrophages 
ADCC  Antibody dependent cell-mediated cytotoxicity 
TH  T helper cells 
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TNF  Tumor necrosis factor 
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GC  Glucocorticoid 
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DX  Dexamethasone 
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Abstract 
Natural (innate) immunity exhibits impaired basic activity and balance in many clinical 
situations but until recently the research into its important role in host defense mechanisms 
was particularly concerned with malignant tumors. In tumor patients, a great number of 
cellular parameters of the natural immune system show decreased activity which are 
correlated with the progression of the disease. Therefore immunomodulatory treatments 
should aim at a regular improvement of the innate immune functions and in this manner 
support the effect of other therapy modalities. Research into a plant lectin, Viscum album 
agglutinin (VAA)-I is a good example of this aim. VAA-I belongs to the type II ribosome 
inactivating proteins and it has been shown to induce both cytotostatic/apoptotic and 
immunomodulatory effects in cultures of various eukaryotic cells in vitro. In 24h culture of 
human peripheral lymphocytes, a dose-dependent VAA-I-induced apoptosis between 10 
ng/ml and 1 µg/ml lectin concentration was established. After 24h incubation of peripheral 
blood mononuclear cells [PBMC] with non-cytotoxic concentrations (1 ng/ml -10ng/ml), 
VAA-I induced mRNA expression and enhanced secretions of proinflammatory cytokines. It 
was also found that the binding of FITC-conjugated VAA-I to monocytes and granulocytes 
were higher than to lymphocytes. Natural killer (NK)-cells were stimulated by VAA-I in vitro 
in an additive manner which was enhanced by combining it with IL-2 and IL-12. In cultures 
of PBMC and bone marrow CD34+ cells, coincubation of VAA-I with various hematopoietic 
growth factors induced a dose-dependent increase in clonogenic growth. In vivo, VAA-I is 
also able to stimulate the cellular parameters of natural immunity with a bell-shaped curve of 
efficacy. Studies in animal models confirm that application of 0.5-3 ng/kg VAA-I twice a 
week effectively sustains elevation in number and activity of peripheral blood NK cells. In 
healthy persons, these parameters often exhibit high intrinsic fluctuations, but  blind crossover 
studies reveal an optimal lectin dose of about 0.5 and 1 ng/kg bw suggesting a potential use of 
  
5
5
mistleoe lectin as a modulator of the natural immune system. Selective apoptotic effect of 
VAA-I may represent a novel approach for pharmacological manipulation of balance  
between cell growth and programmed death using mistletoe lectin.  Recent studies 
demonstrate that VAA-I is able to modulate the maturation of thymocytes in vivo. In Balb/c 
mice, the total cell count of thymocytes showed significant increase after repeated injections 
of 1 or 30 ng/kg VAA-I and an elevated percentage of apoptotic cells was also found. Single 
positive (SP) thymocytes revealed higher increases in lectin-induced apoptosis than double 
negative (DN) or double positive (DP) cells. In addition, both lectin doses significantly 
inhibited the dexamethasone (DX)-induced reduction of all thymocyte subpopulations 
investigated.  In addition, an additive effect of lectin on DX-induced apoptosis of thymocytes 
was also observed, VAA-I and DX having different activities. Treatment with 30 ng/kg VAA-
I for four days elevated the GCR level (mean fluorescence intensity) in DP thymocytes. In 
conclusion, it can be established that VAA-I is an effetive immunomodulator but judgment of 
a possible clinical benefit of these results requires further preclinical and clinical research.  
1.) Introduction 
1.1. Several new aspects in research of natural (innate) immunity: why is it important for 
clinical research? 
An old goal of the medical therapy of  various clinical situations in which the immune system 
is defective has been to aim at a long-term stimulation of natural resistance and thus to attain a 
clinical benefit without toxic side effects. Since experimental and clinical medicine has often 
had difficulty to define the exact role of natural host  defense mechanisms in a great number 
of diseases, these issues were often  dealt with under the so-called “natural medicine”. 
However, the immunomodulatory treatments must not be a part of  “alternative medicine”.    
1.1.1. Definitions of natural immunity   
It is well known that natural immunity is an essential part of the first and last line of host 
defense which can be rapidly mobilized and that the neuroendocrine system is an important 
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regulator of its activity [1]. Many years ago, the members of the natural immune system, such 
as polymorphonuclear neutrophils (PMNs), macrophages, natural killer (NK) cells, gamma-
delta T lymphocytes, dendritic cells and CD5+ B lymphocytes were defined as cells that they 
can recognize cells lacking the surface expression of major histocompatibility complex 
(MHC)-class I molecules and can act non-specifically against various microorganisms and 
tumor cells. However, it was often forgotten that one of the most important characteristics of 
the natural immune system is a continuous regulation of the “basic” activity of their effector 
cells which may possibly prime these cells to determine their reactivity to “foreign” agents.  
The neuroendocrine system is regularly responsible for their responsiveness but various 
clinical situations can also induce a diminished basic activity of the natural immune system. 
For example, viral infections are able to inhibit several components of innate immunity [2] 
resulting in a viral persistence due to evasion or inactivation of its effector mechanisms. 
Surgical interventions and anesthesia can also lead to impaired functions of natural immunity 
[3-8]. Until recently, the role of altered mechanisms of innate immunity was studied 
particularly in relation to malignant tumors.  
1.1.2. Natural immune system plays an essential role in influencing the immune responses 
towards a protective antitumor activity. 
1.1.2.1. Pathological alterations in the functional activity of T cells infiltrating the tumor 
mass 
T-cell chauvinism was so widespread [9] that the antitumor potential of natural effector cells 
continues to receive insufficient attention, and researchers have not yet fully considered the 
possibility of exploiting their functions as effective weapons against cancer. Growing 
evidence suggest that the tumor microenvironment is able to alter the functional activity of T 
cells infiltrating the tumor mass [10]. The interaction between the specific and general 
inflammatory reaction and its relation to prognosis of cancer patients was often studied. It was 
shown that although a large specific anti-tumor response reflected by T cells, protects against 
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distant metastases, their effect on patient survival and local recurrence are less important than 
the effects of the nonspecific inflammatory response [11]. In addition, defects in the major 
histocompatibility complex (MHC) class I antigen-processing machinery (APM) have been 
described in tumors of different histology. Murine data suggest that defects in the MHC class 
II APM might also be associated with malignant transformation of human cells [12]. 
Malignant transformation of melanocytes may also be associated with changes in the 
expression of the major histocompatibility complex (MHC) HLA class I antigens [13]. HLA 
expression is frequently altered in tumors compared to the tissue from which they originate. 
Given the central role of MHC products in the restriction of T-cell recognition, regulation of 
tumor HLA expression might be a strategy for the evasion of immune surveillance by the 
malignant cells as these HLA defects regularly increase with invasion or progression of 
tumors [14]. Thus, the abnormalities of the antigen-processing machinery in tumor cells can 
contribute to their escape from recognition by T cells.  
1.1.2.2. Role of nonspecific inflammatory effector cells in anti-cancer reactions 
Natural killer (NK) cells, the most evolutionary developed effector cells of innate immunity, 
are implicated in various host defense reactions. In contrast to T lymphocytes, NK cells can 
sense whether cells have lost the surface expression of major histocompatibility complex 
(MHC)-class I molecules. In recent years there has been remarkable progress in our 
understanding of the molecular mechanism regulating natural killer (NK) cell function [15]. 
The discovery of MHC-class I-specific inhibitory receptors clarified the basis for this 
discrimination and elucidated the nature of the 'off' signal. However, the receptors responsible 
for the 'on' signal during natural cytotoxicity remained mysterious. [15]. Recently, an 
apoptosis-inducing ligand was described which is a type II membrane protein belonging to the 
TNF family and plays a critical role in the NK cell-mediated suppression of tumor growth 
[16].  
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It is generally accepted that NK cells are implicated in immune surveillance against tumor 
development but the sensitivity of tumor cells to NK cytotoxicity is different. The spectrum of 
the NK susceptibility to various tumor targets is in many cases greater if NK cells are 
activated to a higher degree. Among the numerous regulating factors IL-2 and IL-12 appear to 
be the most important NK stimulators [17-18].  
Although in most solid cancer types the emphasis is placed on the presence of T lymphocytes 
as a specific anti-cancer reaction [19-21], there is also a role for the nonspecific inflammatory 
reaction since the presence of NK cells [22-23], macrophages [24-26], mast cells [27-29], 
neutrophilic and eosinophilic granulocytes [28-31] as well as dentritic cells [32] have 
prognostic value in various solid cancer types. In a clinical study, the interaction between the 
specific and general inflammatory reaction and its relation to the prognosis of patients with 
rectal cancer was evaluated. It was observed that although  specific anti-tumor responses 
mediated by T cells protect against distant metastases, their effects on patient survival and 
local recurrence are less important than the effects of the nonspecific inflammatory response 
[11]. Consequently, it was thought that the peritumoral presence of the nonspecific infiltrate is 
mainly involved in local control of the tumor process, as elucidated by the clear relation 
between inflammatory reaction and local recurrence. In addition, the nonspecific infiltrate is 
indirectly linked to the prevention of distant metastases by interactions with the specific 
response, as well as by the improved local control [11]. Results in animal models are in 
agreement with these finding showing that T-cells are unnecessary or only play a minor role 
in Cop rat resistance to hepatocarcinogenesis and that the nude parental strain is also likely to 
be resistant to the growth of preneoplastic liver lesions [33]. In some studies in humans, 
infiltration of tumors by leukocytes has been associated with a favorable prognosis [34-36]. 
Polymorphonuclear neutrophils (PMNs) are the most abundant circulating blood leukocytes. 
They provide the first-line of defense against infection and are potent effectors of 
inflammation. Nevertheless, various studies have suggested that PMNs are active in 
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immunosurveillance against several tumors [37-40]. Tumor destruction on the part of 
activated PMNs is achieved through their release of a variety of factors (cytokines, enzymes, 
chlorinated oxidants, etc) whose effects include direct tumor killing, extracellular lysis, 
inhibition of angiogenesis and activation of other reactive cells, resulting in NK cell and 
antibody-dependent cytotoxicity [41]. A further mechanism of PMN-mediated tumor cell 
killing is antibody-dependent cell-mediated cytotoxicity (ADCC) [42-43]. Granulocyte-
macrophage-CSF (GM-CSF) augments the normal PMN ADCC of melanoma, 
neuroblastoma, and colorectal cancer cells [44-46]. The crucial importance of PMNs was 
made clear when their selective depletion abolished the rIL-12-induced antitumor effect [41]. 
Whether PMNs also play a role in IL-12 therapy of human cancer has still to be determined.  
1.1.2.3. Impaired basic functions (priming) of natural immune system in tumor disease. 
There is growing evidence that the basic activity of various effector cells of innate immunity 
diminishes in parallel with the progression of the tumor disease This tumor-induced reduction 
of priming of phagocytic cells is not clearly understood. A great number of experiments have 
tried to find an answer to this phenomenon. For example, an absolute requirement of Mac-1 
for FcR-mediated PMN cytotoxicity toward tumor targets is well documented. Mac-1 
receptor, an important activation marker, shows a diminished expression on phagocytic and 
NK cells due to a tumor-induced immune suppression. Mac-1 (-/-) PMNs exhibit defective 
spreading on Ab-coated targets, impaired formation of immunologic synapses, and lack of 
tumor cytolysis [47]. When the effect of malignant glioma cells on the maturation of dendritic 
cells (DCs) was investigated, it was found that IL- 12 production by DCs was inhibited by 
coculture with glioma cells. However, proinflammatory stimulation restored the production of 
IL- 12 by both human and mouse DCs. These data suggest that tumor cells can suppress the 
maturation of DCs [48]. Abnormal differentiation of DCs is an important factor in tumor 
escape from immune-system control. A close association between expression of linker histone 
H1(0) and DC differentiation in vitro has been found. DC production in H1(0) -deficient mice 
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was decreased  significantly [49]. Tumor-derived factors considerably reduced H1(0) 
expression in hematopoietic progenitor cells. Thus, H1(0) histone may be an important factor 
in normal DC differentiation and tumor-derived factors may inhibit DC differentiation by 
affecting H1(0) expression [49].   
Soluble factors produced or induced by malignant cells can be responsible for depressed basic 
activity of the natural immune system. In a clinical trial, the functional properties of 
mononuclear phagocytes isolated from ascitic fluid from patients with peritoneal 
carcinomatosis (PC) was investigated and compared with peripheral monocytes of patients 
and healthy control volunteers [50]. The results of this study showed that, contrary to 
peripheral blood monocytes where phagocytic function was not altered, tumor-associated 
macrophages (TAM) had impaired phagocytic activity. Moreover, dilutions of crude 
supernatant from short-term cultures of these peritoneal cells caused a significant, dose 
dependent inhibition in phagocytosis of control peripheral blood monocytes and peritoneal 
macrophages (PEM), indicating that a soluble factor(s) plays a prominent role in this 
phenomenon. In addition, it was also found that TAM produce fourfold lower levels of NO 
than PEM from control subjects [50]. These data support the hypothesis that depressed TAM 
function may contribute to the mechanisms of tumor escape from immune destruction.  Figure 
1 and 2 demonstrating some examples originate from previous results of the author [117-118].  
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Figure 1.  Priming of granulocytes in peripheral blood of 14 healthy control persons and 28 
breast cancer patients tested by chemiluminescence assay during zymosan phagocytosis. The 
values are expressed in counts per minute (cpm). Each point represents one person and the 
bare represent the mean values for each group. The examinations of the patients were carried 
out during therapy-free intervals [118]. 
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Figure 2. Mean frequency of circulating NK (Large granular lymphocytes = LGL) cells in 
blood of 56 healthy persons, 31 breast cancer patients with stage I or II disease and 42 
patients with stage III or IV disease. The differences between the subgroups are significant 
[117].  
 
1.1.2.4. A modulation of the natural immune system is still not an established treatment in 
cancer immunotherapy and some undesired side effects must also be taken into consideration.  
It is generally accepted that interactions between the immune system and malignant cells play 
an important role in tumorigenesis. Failure of the immune system can represent mechanisms 
by which tumor cells escape from immune-mediated rejection. Many of these mechanisms are 
now known on a cellular and molecular level [51]. Despite this knowledge, cancer 
immunotherapy is still not an established treatment in the clinic. It is also well established that 
cancer is a progressive disease, occurring in a series of well-defined steps, arising typically as 
a consequence of activating mutations (oncogenes) or deactivating mutations (tumor 
suppressor genes) in proliferating cells. 
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An uninterrupted, induced activation of innate immunity as biomodulatory tumor therapy is 
not always beneficial or feasible. Persistent infections within the host induce chronic 
inflammation. Leukocytes and other phagocytic cells induce DNA damage in proliferating 
cells through their generation of reactive oxygen and nitrogen species that are produced 
normally by these cells in order to fight infection [52]. Unfortunately, these react to form 
peroxynitrite, a mutagenic agent [52]. Therefore a permanent inflammatory response can have 
dual effects on the progression of the cancer. On one hand, inflammatory cells are 
prognostically a good sign, probably by maintaining control due to elimination of tumor cells, 
while on the other hand overproduction of reactive species, cytokines and growth factors can 
provide a growth stimulating microenvironment for the cells. Another problem that arises is 
that each inflammatory stimulation initiates cascade mechanisms inducing counter-regulatory 
responses which can attribute to an permanent alteration of the homeostatic immune balance. 
It was established that natural immune cells, such as PMNs [53], macrophages [54]or dentritic 
cells [55] can also modulate the balance between humoral  and cell-mediated immunity by 
contributing to the promotion of a TH1 or TH2 response. Two distinct macrophage 
populations (M1 and M2) regulate  CD4+ T cells. M1 and M2 cells exert opposite effects on 
Th-cell development. M1 cells generate IL-12 which facilitates the development of Th1 cells, 
whereas M2 cells generate IL-10 which facilitates the generation of Th2 cells. Th1 cells 
release IFN-gamma, which stimulates M1 cells and inhibits M2 cells, whereas Th2-produced 
IL-10 inhibits M1 cells and promotes the generation of M2 cells. Through the release of IL-1 
and TNF-alpha, M1 functions as a proinflammatory macrophage, whereas M2 cells, by virtue 
of IL-10 production, act as anti-inflammatory macrophages [54]. Interestingly, tumor patients 
can have up to 40% more M2 peripheral monocytes which in healthy individuals represent 
only 10% of blood monocytes [55]. If DCs derived from  M1 CD16(-) monocytes or from M2 
CD16(+) monocytes (mo1DC and mo2DC) were compared, similar differences were found 
[55]. CD16(-) mo1DC cells stimulated with proinflammatory agents expressed increased 
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levels of IL-12 p40 mRNA and secreted greater amounts of IL-12 p70 than CD16(+) mo2DC, 
whereas levels of transforming growth factor-beta1 mRNA were higher in CD16(+) mo2DC. 
Moreover, CD4(+) T cells stimulated with CD16(+) mo2DC secreted increased amounts of 
IL-4 compared to those stimulated by CD16(-) mo1DC [55]. These data demonstrate that both 
moDCs are not equivalent, suggesting either that they reach different stages of maturation 
during  culture or that the original monocytes belong to cell lineages with a distinctly different 
ability to differentiate. 
Therapeutic modulation of innate immunity requires a long-term support of M1/Th1 functions 
which are responsible for the basic activity of cellular host defense. However, it must be taken 
into consideration that persistent stimulation of M1/Th1 lineage is not possible and therefore 
persistent inflammatory reactions often lead to an alteration of balance towards M2 
development. Furthermore, if the immonomodulatory therapy is not optimized, it can cause 
undesirable side effects. 
The study of  the plant lectin, Viscum album agglutinin (VAA)-I represents a new model to 
look for an answer to these problems. 
1.2. A review of previous research with the plant lectin (VAA-I) as effective biomodulator.  
1.2.1. Mistletoe extracts have been used as immunomodulators for more than 70 years.  
Mistletoe extracts have been given to a large number of cancer patients because of their 
modulatory effect on the natural immune system. By carefully removing lectins, an essential 
component of mistletoe extracts, a significant reduction of their effectiveness on several 
cellular immune parameters could be observed in vivo [56].  That is the reason why, for the 
last fourteen years, the biological research of mistletoe extracts has focused on lectins. The 
quantitatively dominant lectin, Viscum Album Agglutinin (VAA) - I is also now available in a 
recombinant form (rVA A). Other components of the plant extracts such as viscotoxins [57-
58], poly- and oligosaccharides [59], flavonoids [60-61], membrane lipids [62] and arginin 
[63] have also been discussed in connexion with the effects of mistletoe extracts on the host 
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defense.  So far, however, little evidence has been found that support the contribution of these 
substances to the effects of mistletoe in vivo. 
1.2.2. Structural properties of Viscum album agglutinin (VAA)-I as active substance in 
mistletoe extracts.  
So far, mainly the mistletoe lectins and their sugar-binding B-chain have been considered to 
be responsible for the immunomodulatory effect of mistletoe extracts [56].  In all mistletoe 
extracts, mistletoe lectins are present in various concentrations.  Lectins are sugar-binding 
proteins that are able to recognize and bind the glycan part of glycoconjugates (such as 
glycoproteins, glycolipids, oligo- and polysaccharides) specifically [64]. Lectins are 
widespread in all living organisms. However, with regard to their physiological functions, 
much is still unknown.  An important characteristic property of lectins is their ability to 
agglutinate erythrocytes in vitro. That is why they are frequently called "agglutinins“, (for 
example phythemagglutinin).  For mistletoe lectins, a similar nomenclature is also used i.e. 
Viscum album agglutinin (VAA). The lectins are classified according to their sugar 
specificity. This classification is based on the monosaccharide that can cause the greatest 
effect in the lectin-induced agglutination of erythrocytes or in precipitation of carbohydrate 
containing polymers. 
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Figure 3. The structure of VAA-I. The bright part represents the ribosome inactivator A chain 
with enzymatic active site. The dark part shows the B chain with two galactoside-binding 
receptors which is responsible for its immunomodulatory efficacy (A kind gift from Madaus 
AG, Cologne, Germany).   
 
With regard to antigenity and chemical structure, there are three similar lectins in mistletoe 
plants [65-66].  The most important and most often investigated lectin in mistletoe extracts is 
the galactoside-specific VAA-I. It consists of a cytotoxic A-chain with a molecular weight of 
29 kd and a carbohydrate binding B-chain of 34 kd that is responsible for its immuno-
modulatory efficacy. VAA-II, or mistletoe II, with galactoside as well as N-
acetylgalactosamine specificity and mistletoe III with N-acetylgalactosamine specificity could 
also be degradation products of VAA-I in the plants themselves [66-69]. At present, the 
evaluations of mistletoe II and III are not in agreement. So far, some teams have only found 
  
17
17
two groups of isolectin: galactoside-specific VAA-I and N-acetylgalactosamin-specific VAA-
II [70]. The structural analysis of VAA-I and its physical, chemical as well as biological 
characteristics reveal many similarities with the ricin molecule [66, 71-72]. The A-chain of 
VAA-I is a potent ribosome inactivator. The carbohydrate binding B-chain is responsible for 
the internalization of the lectin molecule (uptake into the cell). The B-chain binds terminal 
galactoside residues on the cell membrane preferring certain confirmations [73].  It is this 
chain that brings about the entrance of the whole lectin molecule into eukaryotic cells. The A-
chain, on account of its highly specific enzymatic efficacy, catalytically inhibits  protein 
synthesis in the 28S subunit of rRNA [69, 74-76].  That is the reason why VAA-I, similar to 
ricin, abrin (lectin from the red seed of abrus precatorius), modeccin and volkensin, belongs to 
the type II family of ribosome inactivating proteins with numerous homologous structures 
[66, 77].  In addition to the type II of RIP with two chains, a large number of the one-chained 
type I of RIP, such as gelonin (glycoprotein from the indian plant: gelonium multiforum) or 
trichosanthin (cytotoxic protein from the roots of the chinese drogue: wangua trichosantes 
kirolowii and cucumeroides) have been described [77]. They were isolated from a variety of 
phylogenetically independent plant species so that the RIPs (type I and II) obviously belong to 
an early evolutionary development.  
During the last few years, the primary structure of VAA-I has been analyzed. A strong 
homology to ricin and abrin was found [78-79]. The first cloning experiments for VAA-I were 
made by H. Lentzen, J. Eck, A. Bauer and H. Zinke [European Patent, EP 075 1221 B1 
(1995)].  Expression in E. Coli resulted in the production of the functionally active 
recombinant A- and B-chains that were linked to an active hololectin. The recombinant VAA 
(rVAA) showed similar biological activity (cytotoxicity, RIP activity, induction of apoptosis, 
selective binding, release of cytokines and stimulation of NK function) to the plant extract 
(VAA-I) [80-82]. 
1.2.3. Biological activity of mistletoe lectin (VAA-I)   
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From its biological activity, mistletoe lectin can be regarded as a direct cytostatic as well as an 
immunomodulatory agent. In cultures of human peripheral mononuclear cells (PBMC), VAA-
I stimulates cytokine production as well as programmed cell death (apoptosis) at the same 
concentration [83-86]. These effects are interesting because plant lectins often imitate 
endogenous lectins which may represent old primitive mechanisms in that they eliminate cells 
which  show altered sugar structure on the membrane.  
1.2.3.1. Cytotoxic, cytostatic and apoptotic effects of VAA-I in vitro. 
If eucaryotic cells are incubated for 24 h in the presence of VAA-I, this lectin can be 
cytotoxic in the picogram range as for example in K562 (human erythroleukemia) cells or of 
EL-4 (mouse thymoma) cells [83-84]. In cultures of human peripheral mononuclear cells 
(PBMC), VAA-I starts to have a cytostatic as well as cytotoxic effect above 10 ng/ml if 
incubated for 24h [85]. If incubation is shorter this toxic concentration is of course, higher. It 
could also be proved that the growth inhibiting effect of mistletoe extracts and VAA-I in 
different cell cultures in vitro is due to the induction of programmed cell death (apoptosis) 
[83-84].  When human peripheral lymphocytes (PBL) were incubated for 24 h with VAA-I in 
a concentration ranging between 1ng and 1 µg/ml, flow cytometric analysis with propdium 
iodide (PI) in hypotonic buffer solution and the quantitative assessments of DNA fragments 
with terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-digoxigenin nick end-
labeling (TUNEL) assay confirmed that VAA-I induced a dose-dependent apoptosis above 10 
ng/ml concentration [87].  Monocytic leukemia (THP-1) cells and thymocytes also showed 
apoptosis in presence of VAA-I above 1 ng/ml concentrations. 24h incubation of PBL with 
VAA-I above 10 µg/ml caused necrosis [87]. The isolated A-chain caused similar apoptotic 
effects, the B chain was ineffective [87]. These results indicate that for the apoptotic effect of 
the whole lectin molecule, the A chain, which induces inhibition of protein synthesis, is 
responsible. PBL showed variable sensitiveness to VAA-I induced apoptosis: NK, CD19+ > 
CD8+ > CD4+ cells [81]. Activated lymphocytes (CD25+, CD69+ and HLA-DR+ cells) were 
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also more sensitive to lectin-induced apoptosis than non-activated cells (unpublished data). In 
different lymphocyte populations, selective modulation of Fas antigen by VAA-I indicates 
that Fas antigen-activated signalling can at least partially play a role in VAA-I-induced 
apoptosis [81].  In the early stage of apoptotic cell death, a phospholipid inversion takes place.  
The phosphatidylserin expression is ascertainable by Annexin-V binding. Thus it was found 
that VAA-I (100ng/ml) – induced apoptosis changes into increasing necrosis after 48h. In 
cultures of U937 promonocytes, VAA-I  (30-100 ng/ml) causes increased cytosolic Ca2+ 
which, among other things, is a sign of apoptosis [88].In addition, VAA-I could enhance the 
stimulating effect of  histamine (H1) and complement (C5a) on cytosolic Ca2+ concentration 
that play an accelerating role in the regulation of apoptosis [88]. It is also suggested that 
caspase-3 is involved, at least in part in the apoptotic effect of VAA-I [89].   
Not only lectins with RIP activity cause apoptosis. Griffonia simplicifolia 1-B4 and wheat 
germ agglutinin (WGA) stimulate programmed cell death in cultures of various cell lines [90].  
With regard to the apoptotic effect of lectin-sugar interactions on the cell membrane, the 
question arises whether this is only an in vitro phenomenon or whether it has therapeutical 
relevance? Further preclinical and clinical research is necessary to answer these questions. 
The recent in vivo trials will reported in chapter 3.  
1.2.3.2.Lectin-induced gene expression and secretion  of  proinflammatory cytokines in vitro.  
The investigation of the effect of mistletoe extracts on the cytokine network can also be of 
great significance because it allows a better interpretation of its immunomodulatory efficacy. 
The results of cytokine research with regard to mistletoe have been obtained almost 
exclusively from in vitro data that cannot be directly applied to in vivo situations. In vivo 
cytokines are active in very low concentrations in a complex network. In vivo effective 
immunomodulators, such as mistletoe extracts standardized with regard to lectin content can 
only bring about short-term changes in serum concentrations of cytokines and only to a very 
small degree (picogramme range) [85]. Proinflammatory cytokines, such as interlekin (IL)-1, 
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tumor necrosis factor (TNF)-α and IL-6 in physiological concentrations can be antitumoral, 
antiviral, antimicrobial, antiautoimmune and  radioprotective and can play an important role 
in regulation of innate immunity, cell growth, cell differentiation and in the regulation of  
neurovegetative functions [91]. However, higher and pathological levels of the 
proinflammatory cytokines can have dual effects which result in more risk than benefit [91].  
In 24h culture of PBMC, low and non-toxic lectin concentrations (with an optimum between 1 
and 10ng/ml) stimulate the release of IL-1, IL-6 and TNF–α dose-dependently [85].  D- 
galactose, a monosaccharide with the highest affinity to VAA-I, blocks TNF-α release 
competitively [85]. Mannose that shows no affinity to VAA-I, has no effect in a comparable 
concentration [85]. These results confirm that sugar-protein interaction mediated by the sugar-
binding B-chain is fundamental to the immunomodulating effect of VAA-I. An enhanced 
expression of TNF-α mRNA was induced in human monocytes and in macrophages 
originating from endotoxin resistant (C3H/HeJ) mice, if these cells had been incubated with 
VAA-I for two hours [92]. After 24h incubation of human PBMC with non-cytotoxic 
concentrations of VAA-I (1 ng/ml and 10 ng/ml) the expression of mRNA was measured for a 
series of cytokines by the reverse polymerase chain reaction (rPCR) [86]. VAA-I  induced 
gene expression of IL-1α and β, IL-6, TNF-α, interferon (IFN)-γ and granulocyte-monocyte 
colony stimulating factor (GM-CSF) but no expression of IL-2 and IL-5 could be found [86]. 
Non-cytotoxic concentrations of other mistletoe lectins (II-III) could also induce increased 
secretion of proinflammatory cytokines in monocytes isolated from peripheral blood [93].  So 
far, the investigation of mistletoe-induced cytokines leads to the asumption that monocytes 
are the most important site of origin. This hypothesis seems to be supported by the fact that 
monocytes can bind fluorescent labelled VAA-I molecules with a considerably higher affinity 
than lymphocytes [86]. Thus lectin-sugar interactions on the cell  membrane of monocytes 
can play an important role in the proinflammatory effect of VAA-I. In cultures of monocytic 
THP-1 cells, VAA-I increased the concentrations of inositol phosphatase and 
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phosphatidylinositol indicating lectin-iduced signal transduction in monocytes [94]. The 
preferential effect of mistletoe extracts on the natural immune system is not restricted to 
monocytes. Granulocytes, also, show a higher affinity for VAA-I than lymphocytes [86]. In 
cultures of lymphocytes, VAA-I increased the concentration of HLA-DR+ lymphocytes and 
NK cells and induced gene expression of cytokines [86]. When the ED50 values of lectin 
binding rates of different lymphocyte subpopulations were compared with each other, the 
following sequence was found: NK, CD19+ > CD8+ > CD4+ [81]. 
The in vitro ability of mistletoe lectin to stimulate proinflammatory cytokines has also been 
used for the biological standardization of medicaments. In a skin model system, VAA-I (0.75 
– 8 ng/ml) given in isolated form or as a mistletoe extract caused a dose-dependent increase in 
the  release of IL-1α and IL-6 [95].  Proinflammatory cytokines play a significant role in the 
regulation of natural immunity. They can be responsible at least partially for mistletoe-
induced immunomodulatory effects.  
In addition, another member of the cytokine network, IL-12 that also regulates natural 
immunity, was investigated. In cultures of PBMC, VAA-I increased the secretion of total IL-
12 and its active p70 form [82]. It is well known that I L-12 is important for the adjustment of 
natural killer mechanisms. In addition, it seems that it also plays a key role with regard to the 
regulation of the balance between cellular and humoral immunity which can be altered as a 
consequence of many diseases, for instance advanced cancer [96-97]. On account of such 
interactions this research is of particular clinical significance.  
1.2.3.3. In vitro effects of VAA-I on cellular parameters of natural immunity and on 
hematopoietic progenitor cells of bone marrow. 
More than 15 years ago, the discovery was made that VAA-I and its B-chain stimulate the 
phagocytic activity of human leukocytes [98].  As mentioned earlier, monocytes and 
granulocytes show a higher affinity to VAA-I than lymphocytes [86]. VAA-I induces a higher 
release of oxygen radicals from granulocytes than other lectins [99]. The influx of Ca2+ ions 
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plays a role in the O2 formation of activated phagocytic cells. It was demonstrated that VAA-I 
stimulate the uptake of Ca 2+ into granulocytes. These results support the possibility of a 
lectin-induced galactoside-specific activation of the biosignalling [100]. In vitro VAA-I in 
combination with other cytokines is often more efficient than the lectin alone. For example, 
VAA-I in combination with suboptimal concentrations of IL-2 and IL-12 induced an additive 
increase of NK cytotoxicity of human PBMC or rat spleen cells against NK sensitive target 
cells [82]. These results were confirmed by other investigators [101] who have found 
synergism between IL-12 and VAA-I in the induction of lymphokine -activated killer (LAK) 
activity. In cultures of hematopoietic progenitor (CD34+) cells from bone marrow, VAA-I in 
combination with other hematopoietic growth factors (stem cell factor, IL-3, G-CSF, M-CSF 
and erythropoetin) caused significantly increased proliferation also on synergism [102].  
1.2.3.4. In vivo effects of mistletoe extracts and VAA-I on cellular parameters of natural 
immune system in animal model, healthy volunteers and cancer patients. 
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With regard to cellular immunological reactions in vivo a bell-shaped dose – response 
  
Figure 4. Immunological responses after a single intravenous injection of recombinant lectin 
(rVAA) in rats. Six randomized groups each containing  8 animals were treated once with 
placebo or with various doses of rVAA. Blood samples were collected before, 24h and 48h 
after a single injection. After two days all animals were sacrificed. a. NK-mediated 
cytotoxicity of splenocytes against YAC-1 cells expressed in mean relative augmentations 
[82]. b. Mean relative enhancement in absolute count of LGL (circulating NK cells) in blood 
expressed in ratios to baseline values. c. Mean percentage of CD11b+ (MAC-1+) 
mononuclear cells (monocytes and NK cells) in peripheral blood after 48h. Each value of 
treated groups was compared with control and statistically analyzed. *p<0.05; **p<0.01; 
***p<0.002 [82]. 
  
  
24
24
relationship of VAA-I and mistletoe extract could be observed [56, 103-105]. A single 
injection of pure VAA-I (0.25-1 ng/kg) into rabbits enhances dose-dependently their 
temperature as well as the number and phagocytitic activity of granulocytes, the cytotoxic  
activity of NK cells and the number of large granular lymphocytes (LGL) in peripheral blood 
[56]. The maximum effect was found at 0.8 ng/kg bw [56]. In humans, the optimal effect was 
within the range of 1 ng VAA-I/kg [106], a dose far below the toxic limit. The 50% lethal 
dose (LD50) for mice lies in the region of a few hundred µg/kg [107].  Experiments with 
mistletoe extracts standardized in regard to lectin activity suggest that an immunological 
stimulation induced by an optimal lectin dose  (1 ng VAA-I /kg) can only be initiated again 
after three days without therapy [106].  In rats, recombinant mistletoe lectin (rVAA) also 
shows a bell-shaped dose-respone relationship when activity and frequency of NK cells in the 
blood were investigated after a single injection (Fig.4)[82]. In the case of cancer patients, 
subcutaneous injections of mistletoe preparations with a lectin dose of 1 ng VAA-I /kg twice a 
week led to an elevation of cytotoxic activity and frequency of peripheral NK (CD3-
/CD16+56+) and LGL cells (105). Increased numbers of peripheral lymphocytes, T cells and 
Th cells, enhanced expression of CD25+ and HLA-DQ+ activation markers, as well as higher 
concentrations of acute phase proteins and complement factor C3 could also be observed 
[108-111].  As there were no controlled clinical investigations of the immunomodulating 
efficacy of VAA-I respectively mistletoe extracts, we performed four randomized crossover 
double blind pilot studies with healthy volunteers. For the first and second study a lectin 
concentrate was isolated from mistletoe extracts. The effect of this concentrated lectin 
preparation on different lymphocyte subpopulations (CD3+, CD4+, CD8+, CD3-/CD16+56+, 
CD3-CD25+, CD3-CD69+ and CD3-HLA-DR+) and the cytotoxic activity of NK cells in the 
peripheral blood of  9 resp. 8 persons was tested. In contrast to the significant lectin-induced 
increases in the number of lymphocytes and LGL cells in animal models, healthy volunteers 
did not show any significantly different reactions with regard to the lymphocyte 
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subpopulations mentioned above or NK activity after the same lectin concentrate or salt 
solution [112]. However, when comparing mistletoe-induced reactions with the pretreatment 
values, the elevations in concentration and activity of the NK cells were found to be 
significant only after the lectin concentrate [112].  Because of the considerable intrinsic 
fluctuations of these parameters after placebo treatment, further randomized crossover double 
blind pilot studies with 6 resp. 8 healthy persons were made using a parameter that could be 
assessed more rapidly following the injection and freshly isolated plant VAA-I was given to  
Table 1. Double blind cross over studies in healthy volunteers 
 First trial (n=8)    Confirmatory study (n=6) 
 Placebo  VAA-I  Placebo VAA-I                                
___________________________________________________________________________ 
Relative increases      
in priming of PMN            
5h 0.92 (0.25) 1.94** (0.59)  1.04 (0.31) 3.56**(1.33)  
24h                0.85  (0.29) 1.32* (0.43)  0.8 (0.69) 1.84* (0.88) 
LGL/ml 
0h 656 (163) 540 (173)   639 (205) 555 (204)  
24h 472 (137) 1052* (364)  578 (196) 1131* (395) 
________________________________________________________________________ 
Average increases (95% confidence intervals) of oxidative reactions of circulating 
polymorphonuclear neutrophils (PMN) were assessed 5h and 24h after a single injection of 1 
ng VAA-I/kg body weight or of salt solution compared with pretreatment values. The 
absolute number of LGL cells in peripheral blood was also tested. Statistical analysis was 
carried out between the treated group and the placebo group with the help of paired t test  
(*p<0.05; **p>0.01) [112]. 
 
 
diminish the negative effect of a possible lectin instability in the commercial extract. The 
priming of the granulocytes was tested five hours after the injections. In both studies 
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significant increases  in the priming of granulocytes 5h after the injection of purified VAA-I 
was found as compared to placebo controls (table 1) [112].  
As mentioned above, an immunological stimulation induced by an optimal lectin dose  can 
only be obtained again after three days without therapy [106]. As a consequence of the results 
with low doses, the question arises as to whether a regular application of the immunologically 
active low-dosed extracts twice a week can lead to a long-term increase in the cellular 
parameters of natural immunity. Various independent observations were able to confirm this 
suggestion [113-114].   
Cancer patients often show a correalation between clinical progress, quality of life and 
responses of cellular parameters of the natural immune system. Heiny and Beuth assessed the 
plasma level of β-endorphin together with several immune parameters during the 
immunologically optimized mistletoe treatment of cancer patients. Significant correlations 
were found between the β-endorphin level, the mistletoe lectin-induced immunological 
reactions and the clinical progress [115-116]. As an endogenous opioid, β-endorphin level in 
plasma correlated with well-being and relief of pain [116]. 
1.3.Recent in vivo studies of mistletoe lectin-induced effect on  murine thymocytes. 
1.3.1. In vivo effect of VAA-I on proliferation and apoptosis of murine thymocytes. 
Because proinflammatory and apoptosis-inducing activity of VAA-I has been shown to occur 
in vitro in similar concentrations, it was interesting  to investigate the in vivo effect of VAA-I 
on proliferation and apoptosis of murine thymocytes. For this reason, we have recently 
examined the short- and long-term in vivo effects of VAA-I on thymocyte subpopulations and 
peripheral T cells in a murine (Balb/c) model [119]. The changes of thymocyte 
subpopulations: CD4-CD8- double negative (DN), CD4+CD8+ double positive (DP), CD4+ 
or CD8+ single positive (SP) and mature peripheral T cells was monitored after a either a 
single or repeated injections with 1 ng/kg and 30 ng/kg VAA-I.   
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1.3.2. Galactoside-specific misletoe lectin modulates the dexamethasone-induced apoptosis 
and glucocorticoid receptor level in Balb/c thymocytes. 
Glucocorticoids (GC) play an important role in treatment of malignant diseases [126] and in 
the therapy of a great number of other disorders e.g. autoimmune diseases, rheumatological 
diseases, patients with tissue transplants etc. [127-128]. Since mature and immature T 
lymphocytes, important mediators of the immune response are highly influenced by GC 
therapy [128], investigation of the GC sensitivity of thymocytes is of clinical interest. It is 
known that T cells undergo rigorous selection processes in the thymus to prevent those with 
either autoreactive or nonfunctional T-cell receptors (TCRs) from entering the periphery [129-
130]. GC hormones are also produced by the thymic epithelial cells [131] and are believed to 
play a role in T cell development and selection [132], although their precise mode of action is 
controversial. The difference in glucocorticoid sensitivity of mature and immature 
subpopulations of thymocytes can play an important role in both positive and negative 
selection steps depending on TCR-mediated signal [133]. It was also shown that among the 
thymocyte subpopulations, the most GC-sensitive double positive (DP) thymocytes have the 
lowest GCR level [134]. GCR-deficient thymocytes were resistant to dexamethasone (DX)-
induced apoptosis, confirming the absence of glucocorticoid responsiveness [135]. However 
the absence of genomic GCR action had no impact on thymocyte development either in vivo 
or in vitro since T cell differentiation, including positive and negative selection, was normal 
as judged by the development of CD4+CD8+, αβTCR+CD4+, and αβ TCR+CD8+ 
thymocytes [136]. These results question whether there is a relationship between GCR 
expression and GC hormone action in different cell populations [137].  
In our first study [119] we showed that in vivo administration of a low dose (30 ng/kg body 
weight) of galactoside-specific plant lectin, VAA-I influenced the thymocyte development 
and inhibited the Dexamethsaone (DX)- induced reduction of thymocyte cell number. 
Enhanced proliferation and selection of immature cell populations was the cause of the 
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elevated total thymocyte cell number [119]. In our second study the effect of VAA-I on DX-
induced apoptosis and GCR expression of thymocytes was investigated in the same animal 
model. An additive effect on the total number of apoptotic cells with a higher GCR expression 
in the surviving cells was detected. VAA-I, that can cause an enhanced proliferation of 
immature cells, induced increased apoptosis of the mature single positive (SP) cell 
populations in contrast to DX which had the opposite effect [138]. 
1.4. Principle designs of the present investigation 
1.4.1. Further examination of immunomodulatory effects of lectin (VAA-I). 
1.4.2. Determination of lectin-induced proliferation and apoptosis of  CD4+ and CD8+ 
mature- as well as of DN and DP immature  thymocytes in vivo.  
1.4.3. Investigation of the protective effect of VAA-I on GC-induced reduction of thymocyte 
number. 
1.4.4. Study of the additive effect of VAA-I on GC-induced apoptosis in various thymocyte 
subpopulations. 
1.4.5. Examination of effect of lectin on GCR expression of thymocytes 
1.4.6. New interpretation of bell-shaped dose response curve of lectin efficacy on the basis of  
the present results.  
1.4.7. Further promotion of lectin standardization and reproducibility for preclinical and 
clinical research.  
2. Material and methods 
2.1.Investigation of effect of VAA-I on proliferation and apoptosis of murine thymocytes. 
As previously described [119], VAA-I was prepared from fresh aqueous extracts of the leaves 
and stems of mistletoe plants and purified on lactosylated agarose columns [82]. Endotoxin 
contamination in the samples used was less than 0.5 pg/ml, as determined by quantitative 
kinetic LAL assay. Three groups of three Balb/c mice  were treated subcutaneously with 
placebo (phosphate-buffered saline) or with VAA-I and/or with DX using the following 
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doses: 1 or 30 ng/kg VAA-I alone, 1 or 30 ng/kg VAA-I combined with 1 mg/kg DX. As 
positive control, 1 mg /kg DX was given alone. In the first study, all animals were sacrificed 
24h after one subcutaneous injection. In the second trial the subcutaneous injections were 
administered twice a week for three weeks. 72h after the last injection, all animals were 
sacrificed.  
Thymus glands were removed and placed in ice-cold PBS. Thymus tissue was homogenized 
in a glass/glass homogenizer and the suspension filtered through a nylon mesh filter. The 
thymocytes were washed in PBS and the total cell number and viability were determined by 
counting in a hemocytometer using the trypan blue dye exclusion test. 1 x 106 thymocytes in 
100 µl binding buffer (PBS/ 0,1%NaN3/0,1%BSA) were labeled for the expression of CD4 
CD8 for 30 min on ice. After 2 washing steps in PBS, the cells were stored in 500 µl 
0,1%PFA/PBS buffer until flow cytometric analysis. Apoptosis and cellular DNA content 
were analysed after fixation with 4%PFA. Samples were kept in saponin buffer 
(0,1%saponin/0,1%BSA/0,1%NaN3 in PBS) and incubated with 100µg/ml of DNase-free 
RNase (Sigma) followed by 50µg/ml of propidium iodide (PI SIGMA P 4170) for 30 min at 
room temperature. The samples were analyzed in a FACS Calibur flow cytometer (Becton 
Dickinson, San Jose CA), using the CellQuest software. Thymocytes were gated on forward 
and side scatter plots according to their size and granularity. The gate determined by the 
untreated thymocyte sample was used for all further measurements. Thymocytes were gated 
according to their CD4 and/or CD8 fluorescence. To determine the apoptotic cell number 
using the detection of the DNA content of the cells, PI incorporation into DNA was examined 
in FL-2 channel of the flow cytometer using a linear amplification. In addition, Annexin V 
binding to membrane phosphatidylserine of various thymocyte subpopulations was also 
measured. The results were analyzed with Student’s t test and U test according to Wilcoxon, 
Mann and Whitney using the Statgraphics statistical package for IBM-compatible computers. 
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2.2. Investigation of dexamethasone-induced apoptosis and glucocorticoid receptor level in 
Balb/c thymocytes. 
VAA-I was prepared as described above (2.1).  Dexamethasone (Oradexon, Organon) was 
purchased from N.V. Organon Oss Holland in ampoules containing 5 mg/ml. Apoptosis was 
detected with Annexin-V- FITC (Pharmingen) and propidium iodide (SIGMA P 4170). Anti-
mouse-CD4-PE and anti-CD8-CyChr antibodies were purchased from Pharmingen, anti-
GCR-FITC was prepared in our laboratory [139] and used for intracellular staining.  
Balb/c mice (6 weeks old, body weight approximately 20 g +/-10%) were assigned at random 
to six groups of 3 animals each in both studies. Three animals/group were treated either 
subcutaneously with placebo (phosphate-buffered saline) or with VAA-I and/or with 
dexamethasone (DX) at the  following doses: 1 or 30 ng/kg VAA-I alone, 1 or 30 ng/kg 
VAA-I combined with 1 or 2 mg/kg DX. The subcutaneous injections were administered 
twice a week. All animals were sacrificed after 24h, four days or three weeks. 
The thymus glands were removed and placed on ice-cold PBS. Thymus tissue was 
homogenized in a glass/glass homogenizer and the resulting suspension was filtered through a 
nylon mesh filter. 1 x 106 thymocytes in 100 µl binding buffer (PBS/ 0,1%NaN3/0,1%BSA) 
were labeled for the expression of CD4 and CD8 for 30 min on ice. After 2 washing steps in 
PBS, the cells were fixed with 4% paraformaldehyde (PFA)/PBS for 20 min, washed 2x in 
PBS and stained in saponin buffer (0,1% saponin, 0,1% NaN3, 0,1% BSA) for intracellular 
GCR expression  After 30 min incubation on ice, the cells were washed 2x in saponin buffer, 
1x in binding buffer and stored in 500 µl 0,1%PFA/PBS buffer until flow cytometric analysis. 
For the detection of early apoptosis, cells were labeled with Annexin V-FITC for 15 min in 
Annexin buffer after CD4/CD8 staining [140]. For determination of late apoptosis, cells were 
fixed with 4%PFA. Samples were kept in saponin buffer  and incubated with 100µg/ml of 
DNase-free RNase (Sigma) followed by 50µg/ml of propidium iodide (PI, SIGMA P 4170) 
for 30 min at room temperature. The cells were protected from light, prior to flow cytometric 
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analysis. The samples were analyzed in a FACS Calibur flow cytometer (Becton Dickinson, 
San Jose CA), using the Cell Quest software. Thymocytes were gated on forward and side 
scatter (FSC/SSC) plots according to their size and granularity. The gate determined by the 
untreated thymocyte sample was used for all further measurements. To determine the 
expression of GCR positive cells in double negative, double positive and CD4 or CD8 single 
positive populations two parameter dot plots showing cell surface CD4/8 staining were first 
created from the previous gate. Thymocytes were gated according to their CD4 and/or CD8 
fluorescence and these populations were separately analyzed for GCR-FITC log fluorescence 
(FL-1). The fluorescence intensity of GCR staining was compared in different thymocyte 
subpopulations by overlaying the FL-1 histograms. To determine the total apoptotic cell 
number the PI incorporation into DNA was measured in FL-2 channel of the flow cytometer 
using a linear amplification. In addition, the early apoptotic cells after CD4/CD8 staining 
were estimated by Annexin V-FITC binding to membrane phosphatidylserine molecules of 
various thymocyte subpopulations. Statistical analysis was carried out as described above 
(2.1). 
3. Results 
3.1. Effect of VAA-I on thymocyte proliferation  
In the first trial, double negative (DN), double positive (DP), CD4+ and CD8+ single positive 
(SP) cells in the thymus as well as CD4+ and CD8+ cells in peripheral blood of Balb/c mice 
were investigated 24h after a single lectin (VAA-I) injection. As shown in the first three 
columns of Figure 5A, a single injection of different doses of VAA-I did not cause significant 
alterations in the total thymocyte cell count or in the DN, DP and CD4+ cell number (Table 
2A). Only the CD8+ thymocyte number revealed a significant (p<0.0 25) increase (70%) 24h 
after 1ng/kg VAA-I and 44% after 30ng/kg (p>0.05). Therefore, the CD4+/CD8+ ratio in 
thymus 24h after the two different lectin doses fell 39% and 38% (p<0.01; p<0.01 
respectively) (Fig.6C, Table 2A). However, at the same time the CD4+/CD8+ ratio in 
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peripheral blood, elevated 74% after 1ng/kg VAA-I and 55% following 30ng /kg d (p<0.005; 
p<0.01) as illustrated in Fig. 6A. 
In the second long-term trial, Balb/c mice were treated with the same doses of VAA-I lectin + 
DX twice a week for three weeks. 72h after the last injections the same investigations as after 
24h were carried out. As the first three columns of Figure 5B show, the total thymocyte cell 
count in the thymus increased significantly after both lectin doses (p<0.05 and p<0.025, 
respectively). As demonstrated in Table 2B, with the exception of CD4+ cells all investigated 
thymocyte subpopulations (DN, DP and CD8+ cells) revealed significant elevation after long-
term treatment with 30ng/kg VAA-I (p<0.01; p<0.05 and p<0.0025, respectively). 1ng/kg 
lectin also caused an increase in all cell populations, but significant growth could be measured 
only in the CD8+ thymocyte population, indicating that CD8+ thymocytes in both short- and 
long-term studies were found to be more susceptible to lectin-induced proliferation in the  
thymus. 
3.2. VAA-I inhibited the Dexamethasone-induced thymocyte reduction 
Since it is well known that DX causes considerable reduction in the thymocyte count parallel 
to the lectin induced alterations, we also investigated the effects of VAA-I treatment on short 
(24h) and long-term (twice a week, for three weeks) DX (1mg/kg BW) therapy. As expected, 
DX treatment alone in both cases induced significant reduction in total number of thymocytes 
(p<0.05) (4th columns of Fig. 5A and 5B). This DX-induced reduction of thymocyte cell count 
was significantly less if DX was injected in combination with VAA-I (5th and 6th columns of 
Fig. 5A and 5B). As shown in Table 2B, all investigated thymocyte subpopulations (DN, DP, 
SP) showed significant elevation if DX was combined with VAA-I for three weeks.  
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Table 2. 
A.Effect of single dose VAA-I and DX treatment on thymocyte subpopulations x 106 (SEM) 
Thymus Ctrl VAA 1ng VAA 30ng VAA 1ng 
+DX 
VAA 30ng 
+DX 
DX 
DN  
2,4 (0,4) 
 
3,0 (0,5) 
 
4,7 (0,1) 
 
1,6 (0,4) 
 
1,8 (0,6) 
 
*1,2 (0,1) 
DP  
117,8 
(7,5) 
 
97,1 (1,3) 
 
104,5 (13) 
 
64,4 (14) 
 
55,7 (13,0) 
 
*48,1 
(5,4) 
CD4+  
12,5 (1,4) 
 
12,7 (1,7) 
 
10,5 (1,2) 
 
9,0 (1,7) 
 
8,2 (2,4) 
 
*5,4 (0,2) 
CD8+  
4,9 (1,3) 
 
*8,4 (1,2) 
 
7,1 (1,7) 
 
7,0 (2,8) 
 
6,9 (2,9) 
 
*2,3 
(0,03) 
 
B.Effect of long-term VAA-I and DX treatments on thymocyte subpopulations x 106 (SEM) 
Thymus Ctrl VAA 1ng VAA 30ng VAA 1ng 
+DX 
VAA 30ng 
+DX 
DX 
DN  
3,2 (0,7) 
 
3,5 (0,2) 
 
*4,7 (0,24) 
 
#4,8 (1,6) 
 
#3,0 (0,8) 
 
*0,9 (0,3) 
DP  
48,8        
(14,7) 
 
69,7 
(15,9) 
 
*101 (18,0)
 
#54,4 (16) 
 
#53,7 
(16,7) 
 
*10,2 
(1,5) 
CD4+  
7,2 (1,4) 
 
9,4 (0,9) 
 
10,6 (2,1) 
 
#7,6 (2,0) 
 
#6,3 (1,8) 
 
*2,2 (0,3) 
CD8+  
2,3 (0,3) 
 
*3,6 
(0,08) 
 
*4,4 (0,1) 
 
#3,8 (0,9) 
  
5,0 (3,0) 
 
*0,9 (0,3) 
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Table 2. The average absolute numbers (+SEM) of double negative (DN), double positive 
(DP), CD4+ and CD8+ cells compared after various treatments. (*) indicate that in 
comparison with negative control a p value < 0.05 and (#  ) relates to statistical significance 
(p<0.05) when comparing lectin groups with positive control animals that were treated with 
dexamethasone (DX) alone. 
 
3.3 Effect of VAA-I on apoptosis of murine thymocytes in vivo 
In the first trial, 24h after a single injection of either 1ng/kg or 30 ng/kg VAA-I the 
percentage of apoptotic cells rose 1.9-fold and 2.2-fold (p<0.07 and p<0.05, respectively; see 
Fig 7A). This increase in apoptosis was higher than that caused by 1mg/kg DX treatment, 
suggesting a possible additive effect of VAA-I on DX. To investigate the initial phase of 
apoptosis in a more sensitive manner, the phosphatidylserine expression on the surface of 
thymocyte subpopulations by Annexin V binding was also determined. As shown in Fig 8, 
24h after a single injection of 30 ng/kg VAA-I, CD4+ and CD8+ SP thymocyte 
subpopulations showed 2 fold and 1.7 fold enhancement in the frequency of apoptosis 
compared to negative control values (p<0.05 and p<0.01, respectively). In the second trial, 
only 30 ng/kg VAA-I (72h after the last injection of a treatment for three weeks) caused (see 
Fig. 7B)  a significant increase (54%) in percentage of apoptotic thymocytes (p<0.01). The 
elevated number of DN and DP thymocytes showing increased apoptosis induced by VAA-I 
may be a reflection of the  more rapid proliferation and enhanced maturation (positive and 
negative selection) of these immature cells resulting in increased number of mature SP cells.  
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Figure 5. Effect of VAA-I on thymocyte proliferation. 
Total numbers of thymocytes in Balb/c mice after treatment with 1 and 30 ng/kg lectin (VAA-
I) and/or Dexamethasone (DX). The experiments were carried out either 24h after a single 
subcutaneous injection (5A) or 72h after the last injection of treatment twice a week for three 
weeks (5B). Each value represents the average of three animals (+SEM). The results of 
various subpopulations and statistical analysis are shown in table 2. 
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Figure 6. Effect of VAA-I on ratio between CD4+ and CD8+ cells.  
The mean ratios (+SEM) between CD4+ and CD8+ cells are shown in peripheral blood and in 
thymus 24h after a single injection (6A and 6C) or 72h after the last injection of a three weeks 
treatment (6B and 6D). 24h after a single injection of both lectin doses this ratio significantly 
decreased (6C) in thymus (p<0.01; p<0.01) and increased (2A) in blood (p<0.01; p<0.05). 
After three weeks (6B and 6D) no significant differences between treated and control groups 
were found. 
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Figure 7. Effect of VAA-I on thymocyte apoptosis 
Mean percentage (+SEM) of apoptotic cells in thymus 24h after a single injection of lectin 
(7A) or 72h after the last injection of treatment twice a week for three weeks treatment (7B). 
30 ng/kg lectin induced significant enhancement in both trials (p<0.05; p<0.01).  
 
 
 
 
Figure 8.  Effect of VAA-I on apoptosis of thymocyte subpopulations. 
Mean augmentation [(experimental value / negative control value) + SEM] of apoptotic 
thymocyte subpopulations 24h after asingle injection of VAA-I or DX. All investigations 
were carried out with Annexin V staining of mouse thymocytes. 30 ng/kg lectin induced 
significant increases in apoptosis of CD4+ and CD8+ SP subpopulation (p<0.05 and p<0.01).  
 
3.4. Effect of VAA-I on DX-induced thymocyte apoptosis    
Effects of a single injection of 30 ng/kg VAA-I alone or in combination with 1 mg/kg DX on 
the percentage of apoptotic cells in various thymocyte subpopulations were investigated. As 
shown in Fig 9, detection of early apoptosis in thymocte subpopulations by Annexin V-
binding revealed that VAA-I alone induced significant increases in apoptosis of SP (CD4 and 
CD8+) subpopulations. However, there was a small difference between the augmentation of 
apoptosis in SP cells caused by the lectin alone or in combination with DX: 2.0fold and 
2.1fold increases of CD4+ cells; 1.69fold and 1.82fold elevations of CD8+ cells (Fig 9). 
Interestingly the lectin caused diminished apoptosis in DN cell populations, while in the DP 
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cell population no significant alteration could be observed. DX alone induced enhanced 
apoptosis in DN, DP and CD4+ cell populations (P= 0,09, P<0,05 and P<0,01 respectively).  
Combined treatment induced similar effects to those induced by DX alone on immature cell 
groups.  
After four days or three weeks, the percentage of late apoptotic cells in total thymocyte 
populations was investigated by PI incorporation into DNA. The combination of VAA-I given 
on day 0 and day 3 with continuous DX therapy for four days caused enhanced apoptosis of 
total thymocyte populations (23+/-3.1%) compared to the DX treatment alone (15,1%+/-1.7; 
p<0.05) (data not shown). As illustrated in Fig.10, 72 hours following the last administration 
of treatment with 30 ng/kg VAA-I alone (twice a week  for three weeks) 54% enhancement  
(p<0.01) of total apoptotic thymocytes was detected while the 3 weeks treatment with DX 
alone caused only an increase of 13% (p>0.05). Combined treatment (lectin injections twice a 
week together with DX) resulted in an additive increase (2-fold) in percentage of apoptotic 
thymocytes (p<0.05). 
3.5. Effect of VAA-I on the glucocorticoid receptor (GCR) level in thymocyte subpopulations  
The previously described lectin-induced proliferation of immature thymocyte subpopulations 
which effectively inhibited the DX induced depletion of the thymus and its apoptotic effects 
on mature thymocytes (present trial) raised the question whether VAA-I influences the 
expression of intracellular GCR level in thymocyte subpopulations. 24h after a single 
injection of VAA-I, the GCR mean fluorescence intensity (expression) in thymocyte 
subpopulations did not alter significantly (data not shown). Treatment with 30 ng /kg VAA-I 
for four days caused a 2.5fold increase in GCR mean fluorescence intensity of DP thymocytes 
(p<0.05) but only a 1,17fold elevation of  DN thymocytes (p>0.05) (Fig. 11). The third group 
of Balb/c mice was treated with 30 ng/kg VAA-I twice a week for three weeks. 72h after the 
last injections the same investigations as after 24h and four days were carried out.  The GCR 
expression (mean fluorescence intensity) of thymocytes increased similarly in all 
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subpopulations: 25% GCR of DN, 23% of DP, 27% of CD4+ and 20% of CD8+ cells (see 
Fig. 12; p values >0.05).  
 
 
Figure 9. Effect of VAA-I on apoptosis of thymocyte subpopulations. The bars represent the 
apoptosis index [(percentage of Annexin positive thymocytes in treated mice / percentage of 
Annexin positive thymocytes in untreated control) + SEM] of thymocyte subpopulations 24h 
after a single injection of VAA-I and/or DX. 30 ng/kg lectin alone and/or in combination with 
DX induced significant increases in apoptosis of CD4+ and CD8+ SP subpopulations 
(*p<0.025; **p<0.01; +p<0.001 and ++p<0.025, respectively). DX alone caused elevation of 
apoptosis in DN, DP and CD4 SP thymocytes (#p<0.09; ##p<0.05, ###p<0,01). 
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Figure 10. Effect of repeated VAA-I treatment on DX-induced thymocyte apoptosis. The 
apoptotic index (+SEM) of all thymocytes 72h after the last injection of repeated (3 weeks) 
treatment with 30ng/kg VAA-I and / or 1 mg/kg Dexamethasone are illustrated. VAA-I both 
alone and in combination with DX induced significant enhancements in the number of 
apoptotic cells (*p<0.01 and **p<0.05).  
  
40
40
0,0
0,5
1,0
1,5
2,0
2,5
3,0
0,0
0,5
1,0
1,5
2,0
2,5
3,0
**
*
VAA-I               -                   -                   +                +
DX                   -                   +                   -                 +
 
 A
po
pt
ot
ic
 in
de
x 
of
 th
ym
oc
yt
es
 +
 S
EM
 
Figure 11. Effect of VAA-I and DX on the GCR level of thymocytes after a 4 day combined  
treatment. Bars represent the GCR mean fluoresecence intensities (+ SEM) in DP and DN 
thymocytes. The treatment induced significant elevations of GCR expression in DP 
thymocytes (*p<0.05). 
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Figure 12. Effect of 3 weeks VAA-I and / or DX treatment on the GCR level of thymocyte 
subpopulations. Mean fluorescence intensities of GCR staining (+SEM) in DN, DP, CD4 and 
CD8 thymocytes are shown. 72 hours after the repeated VAA-I treatment no significant 
alteration in GCR expression (p values >0.05) could be observed. 
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4. Discussion 
Our studies showed that in agreement with previous in vitro findings [81, 87], VAA-I can act 
in vivo on the regulation of thymus function inducing both proliferation and apoptosis of 
thymocytes. The short- and long-term effects of VAA-I on thymus proliferation revealed 
responses of both mature and immature cells. These effects at least in part may be related to 
the proinflammatory activity of VAA-I [82] since IL-1β, IL-6, TNFα and IFN are known to 
play an important role in proliferation and apoptosis of thymocytes [120-125]. Whether or not 
there is a direct effect of the lectin on the thymocytes or whether it is a consequence of the 
lectin-induced proinflammatory cytokines has yet to be determined. 
VAA-I was also found to modulate protein synthesis and to induce apoptosis in various 
eukaryotic cells in culture. The apoptotic effect of VAA-I is dose-dependent and involves 
caspase-3 at least in part [89]. In vitro VAA-I can induce a characteristic programmed cell 
death in concentrations between 10 and 1000 ng/ml after 24h in various cells of immune 
origin [81, 89]. In the present in vivo study, a dose as low as 1ng/kg VAA-I appears to be 
more effective during DX therapy in reconstitution of lymphoid tissues than 30 ng/kg. 
However, the higher lectin dose (30 ng/kg bw) was more effective in enhancing the  
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proliferation rate and percentage of apoptotic thymocytes. This observation indicates that 
VAA-I induced apoptosis may be a consequence of the enhanced selection steps in contrast to 
the direct apoptosis induced by DX in immature thymocytes. Our finding, that long-term 
VAA-I can inhibit the DX-induced reduction in thymocyte number, may indicate the 
importance of studying the effect of lectin on the glucocorticoid treatment of various diseases. 
Further investigations are necessary to clarify this question.  
Immunosuppression due to the inhibition of expression of a wide variety of activation-
induced gene products is perhaps the best known biological effect of GCs on peripheral T 
cells [128, 133]. In the thymus, GCs are also potent inducers of apoptosis, and even GC 
concentrations achieved during a stress response can cause the death of CD4+CD8+ (DP) 
thymocytes [135]. Endogenous GCs produced by the thymic epithelial cells are important in 
the positive selection of DP thymocytes which interestingly express the lowest GCR level 
[134]. In contrast an increased GCR gene dosage in mice has been shown to enhance the 
glucocorticoid-induced apoptosis of thymocytes [141]. These effects underscore the 
importance of a tight regulation of GCR expression in the the control of physiological and 
pathological processes.  
As described in chapter 3, VAA-I induced a dose-dependent increase in numbers of both 
immature and mature thymocyte subpopulations [119]. Furthermore, it has been also observed 
that VAA-I is able to modulate the circulating pool of certain lymphocyte subpopulations [82, 
114]. There was a significant difference between the lower doses (between 0.5 and 1 ng/kg) 
which enhance the lymphocyte count and the higher amounts  (over 30 ng/kg) which reduce it  
[82]. The homeostatic regulation that controls total thymocyte and peripheral lymphocyte 
numbers is not clearly understood. However, transgenic mice with reduced GCR expression 
show increased thymocyte and T-cell numbers [142]. Thus, it is very probable that 
physiological GC and GCR levels are directly involved in controlling the size of both 
thymocyte and T-cell pools [132]. For these reasons, the lectin-induced enhancement of GCR 
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levels and its additive effect on DX-induced apoptosis of thymocytes may contribute towards 
a better understanding of the different effects of VAA-I given in low (0.5-1 ng/kg) as 
compared to higher (30 ng/kg) doses [143]. In previous studies, VAA-I has been shown to be 
effective with a bell-shaped dose response curve not only on numbers of circulating 
lymphocytes [56, 144]  but also on several cellular parameters of the natural immune system 
[145-146]. In addition, the lower and more immunomodulatory active dose (1 ng/kg) of VAA-
I has been found to be more protective against the DX–induced reduction of total thymocyte 
number than the higher one (30 ng/kg). In contrast, the higher dose (30 ng/kg) of VAA-I 
exhibited a stronger apoptotic effect on thymocytes than the lower ones [119]. Therefore for 
the present study, 30 ng/kg lectin was selected to investigate its effect on DX-induced 
apoptosis in various thymocyte subpopulations. This dosage of VAA-I also induced an 
enhanced proliferation of thymocytes with a parallel increase in number of apoptotic cells 
which may reflect an enhanced maturation (positive selection) caused by the lectin treatment. 
The present results indicate that the apoptotic effects of DX and VAA-I on thymocyte 
subpopulations differ: DX is more effective in immature DP thymocytes while VAA-I 
induces enhanced apoptotosis mainly in mature SP (CD4+ and CD8+) subpopulations. 
Consequently, the significant additive effect on the total number of apoptotic thymocytes (see 
Fig 2) may indicate that VAA-I and DX act in different ways and is associated with some 
protective effect against the DX-induced reduction in total cell count. Therefore an additive 
effect of VAA-I on GC hormone therapy may be beneficial if the higher circulating level of 
GC results in a lower sensitivity or resistance.  
Because of the bell-shaped dose response curve of VAA-I, GCs are also known to induce 
apoptosis in thymocytes at high concentrations. At lower concentrations, GCs antagonize 
TCR-mediated deletional signals and allow survival of thymocytes [133]. Therefore further 
investigations are necessary to clarify whether the lectin-induced augmentation of GCR levels 
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may also be involved in its bell-shaped dose-response curve of immunomodulatory or 
apoptotic effects. 
 
5. Conclusions and pharmacological perspectives 
5.1. Although a number of various clinical situations can lead to impaired functions of natural 
immunity, the change most investigated is the tumor-induced suppression of innate host 
defense mechanisms. A therapeutic modulation of basic activity and balance of the natural 
immune system is desirable in many clinical situation. A plant lectin, VAA-I may possibility 
achieve this objective.  With regard to the biological and preclinical research of mistletoe 
lectin, two essentially different effects must be considered: cytostatic / apoptotic and 
immunomodulatory activity.  
5.2. Low , immunomodulatory doses of VAA-I could support a long -term therapeutic 
modulation of the natural immune system which is associated with a protective effect. This 
treatment could be combined with the toxic modalities of various therapies  and also improve 
the quality of life.   
5.3 Higher doses of VAA-I with cytostatic / apoptotic effects could suggest new perspectives 
of how to modulate the balance between cell growth and programmed cell death 
therapeutically.  
5.4. At present, judgment of clinical benefits of an immunologically optimized mistletoe 
lectin is difficult and in many aspects is not feasible. However, growing evidence [147-154] 
suggests that VAA-I is able to improve the clinical situation of patients with a decreased 
responsiveness of their natural immune system. Determination of sugar-binding lectin activity 
by an enzyme linked lectin assay enabled a clinically useful standardization of the 
immunomodulatory capacity of mistletoe extracts.  In a multi-centre clinical study, 689 breast 
cancer patients were treated with extracts containing optimal lectin doses  (1 ng VAA-I/kg 
twice a week) and the side effects of oncological basic therapy modalities (operation, 
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chemotherapy, irradiation and hormone therapy) were compared with a control group 
(n=470). VAA-I significantly reduced the frequency of nausea, problems with appetite, 
depression, tiredness and insomnia [155]. In addition, a beneficial effect on local recurrence 
was also established supporting a possible enhanced basic activity of the natural immune 
system. 
5.5. Recent studies demonstrate that VAA-I is able to modulate the maturation of thymocytes 
in vivo. The total cell count of thymocytes showed significant increases after repeated 
injections of immunomodulatory doses of VAA-I and an elevated percentage of apoptotic 
cells was also found. Single positive (SP) thymocytes revealed higher increaes in lectin-
induced apoptosis than double negative (DN) or double positive (DP) cells. Similarly, small 
lectin doses significantly inhibited the dexamethasone (DX)-induced reduction of all 
thymocyte subpopulations investigated. These results indicate that during a glucocorticoid 
treatment, VAA-I may be an effective immunoprotective biomodulator by diminishing the 
undesired side effects on cellular immunity and immune balance.  
5.6. An additive effect of lectin on DX-induced apoptosis of thymocytes was also observed 
which consisted of two different actions of VAA-I and DX. A lectin-induced enhancement of 
the glucocorticoid receptor level may be also involved. The additive effect of VAA-I on 
glucocorticoid (GC) hormone therapy may be beneficial if the higher circulating level of GC 
causes a lower sensitivity or resistance. Evaluation of this possible clinical benefit   requires 
further preclinical and clinical research. In addition, further studies are required to establish 
the favorable effect of lectin during the treatment of diseases in which programmed cell death 
is defective.      
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